Clinical trials: Dosimetry
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Huntington Disease
Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.
A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.
- Trial name
- NCT05224115
- Testing
- [11C]CHDI-00485180-R, [11C]CHDI-00485626
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Locally Confined Adenocarcinoma of the Prostate
Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy
This will be a phase I study. This phase I study is not a standard drug dose escalation study, but rather a Clinical System Performance Evaluation Trial of a therapeutic device.
- Trial name
- NCT00426959
- Testing
- Image Guided Dynamic Dosimetry
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adrenocortical Carcinoma
Phase 1 Study of 68Ga-R8760
A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
- Trial name
- NCT05999292
- Testing
- 68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radionetics Oncology
Primary Renal Cancer
Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer
The purpose of this study is to investigate the use of an MR-guided linear accelerator to treat early stage renal cancer patients, considered inoperable or in patients declining surgerys.
- Trial name
- SMARTER (NCT07767500)
- Testing
- MRI-guided linear accelerator, Magnetic resonance imaging (MRI)-guided radiation therapy (MRgRT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Coronary Artery Disease
Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI
The purpose of this study is to compare clinical efficiency and patient outcomes using ultra low-dose stress only Tc-99m and solid-state SPECT versus traditional Anger SPECT.
- Trial name
- NCT01373944
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Aspire Foundation
Prostatic Neoplasm
Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit
Prostate cancer is the most common cancer in men. Early detection of primary diseases and recurrence is crucial for patient counseling and management. Conventional imaging modalities (CT-MRI) are limited to detect recurrence.
- Trial name
- PSMA (NCT03183544)
- Testing
- Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit
- Where
- Belgium
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Breast Cancer, Cardiac Toxicity
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications.
- Trial name
- BACCARAT (NCT02605512)
- Testing
- Subclinical cardiac lesions and biomarkers
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Sophie JACOB
Prostate Cancer
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 5 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Trial name
- NCT07542379
- Testing
- 177Lu-FC516
- Where
- China
- Volunteers
- 13 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Neuroblastoma
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
This is a pilot study with the primary purpose to describe organ dosimetry and acute toxicities using no carrier added and carrier added 124I-MIBG PET/CT in patients with neuroblastoma (NB).
- Trial name
- NCT01583842
- Testing
- 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Miguel Pampaloni
Meningioma of Brain
Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
- Trial name
- DATUM (NCT06614205)
- Testing
- tumoral dosimetry by scintigraphy
- Where
- 2 sites in France
- Volunteers
- 11 people
- Sponsor
- Central Hospital, Nancy, France
Metastatic Castration-resistant Prostate Cancer
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo…
- Trial name
- NCT03403595
- Testing
- 177Lu-EB-PSMA-617
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07261631
- Testing
- 68Ga-NNS309, 177Lu-DFC413
- Where
- 9 sites in United States, Canada and 5 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Use of [18F]FECNT in Positron Emission Tomography
This study will examine the use of a new radioactive tracer called [18F]FECNT in positron emission tomography (PET) scanning for measuring dopamine transporter (DAT) in the brain.
- Trial name
- NCT00083629
- Testing
- PET
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer
This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer.
- Trial name
- NCT07373782
- Testing
- Continuous Positive Airway Pressure (CPAP)
- Where
- Belgium
- Volunteers
- 53 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer, Prostate Cancer Metastatic Disease
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
The aim of this study is to assess the safety and dosimetry of [68Ga]Ga-OncoACP3 in patients with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, PSA Level Greater Than 0.2
- Trial name
- OncoACP-3 (NCT06840535)
- Testing
- [68Ga]Ga-OncoACP3
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Recurrent High-Grade Gliomas, Recurrent Glioblastoma IDH Wildtype
[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
This is an investigator-initiated, Phase I clinical trial. It aims to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of a novel radiopharmaceutical, [177Lu]Lu-DOTA-EB-RGD2, in patients with…
- Trial name
- NCT07655869
- Testing
- [177Lu]Lu-DOTA-EB-RGD2
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Beijing Tiantan Hospital
Breast Cancer
Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients
The purpose of this national, multi-site study is to determine the safety and effectiveness of the Contura catheter in breast cancer patients undergoing accelerated partial breast irradiation.
- Trial name
- NCT00882596
- Testing
- Accelerated partial breast irradiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Center of Irvine